Bloody Easy Blood Administration (BEBA)
Information for Transfusionists

For additional education resources, visit www.transfusionontario.org

Donna Berta RN, BScN
Clinical Project Coordinator – Nursing
Ontario Regional Blood Coordinating Network (ORBCoN)

December, 2021
Objectives

After completing this learning participants will be able to:

• Explain the transfusion guidelines (indications, dose, and details) for RBC, platelet and plasma transfusion in adult patients.
• Describe the transfusionist’s actions to ensure safe transfusion administration.
• Identify signs and symptoms and immediate management actions of a possible transfusion reaction.

Consult your hospital’s policies and procedures for additional details specific to your facility.

Links to supplementary information

Summary: Transfusion Checklist (refer to slide 42)

Glossary of Terms & Abbreviations (refer to slides 43-45)
Objectives/Outline

After completing this learning participants will be able to:

• Explain the transfusion guidelines (indications, dose, and details) for RBC, platelet and plasma transfusion in adult patients.

Outline:

<table>
<thead>
<tr>
<th>Transfusion Guidelines</th>
<th>Refer to slide number:</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Topic:</strong></td>
<td></td>
</tr>
<tr>
<td>RBC Transfusion</td>
<td></td>
</tr>
<tr>
<td>Indications</td>
<td>4</td>
</tr>
<tr>
<td>Dose &amp; Details</td>
<td>5</td>
</tr>
<tr>
<td>Platelet Transfusion</td>
<td></td>
</tr>
<tr>
<td>Indications</td>
<td>6</td>
</tr>
<tr>
<td>Dose &amp; Details</td>
<td>7</td>
</tr>
<tr>
<td>Plasma Transfusion</td>
<td></td>
</tr>
<tr>
<td>Indications</td>
<td>8</td>
</tr>
<tr>
<td>Dose &amp; Details</td>
<td>9</td>
</tr>
</tbody>
</table>
Transfusion Guidelines:
RBC Transfusion - Indications

Rationale: Red blood cells transport oxygen from the lungs to the tissue cells. Oxygen is needed for tissue cells to carry out their functions in the body.

Adults, not actively bleeding, consider if:

• Hb less than 70 g/L

• With evidence of impaired tissue oxygen delivery (tachycardia, hypotension, cardiac ischemia, syncope, pre-syncope)
  - Hb 70 to 80 g/L
  - Some specific patients, Hb 80 to 90 g/L

Note: Do not transfuse based on only a Hb value. Patient clinical assessment is required.
RBC transfusion is indicated for symptomatic anemia.

About Blood Production, BEBA Handbook, pages 6-7
Transfusion Guidelines:
RBC Transfusion - Dose & Details

Adults, not actively bleeding:

• 1 unit

• Volume = about 300 mL

• RBC shelf-life: 42 days, Stored at 1-6°C in approved, monitored refrigerator

• Transfuse over 2 hours, slower if Transfusion Associated Circulatory Overload (TACO) risk

• If urgent Hb re-assessment required, test Hb 15 minutes after RBC is transfused

• 1 unit = about 10 g/L Hb increase

• Consider a 2nd unit only if re-assessment (patient’s clinical status, Hb result) indicates need

Canadian Blood Services, Circular of Information [Scroll down, click on Red Blood Cells, Leukocytes Reduced (LR)]
Rationale: Platelets are the first responders in the clotting process to stop bleeding (sticky cells, form the platelet plug).

<table>
<thead>
<tr>
<th>Adults, Consider if: Clinical situation</th>
<th>Platelet count x 10^9</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prophylactic transfusion</td>
<td>Less than 10</td>
</tr>
<tr>
<td>Pre-procedures not associated with significant blood loss</td>
<td>Less than 20</td>
</tr>
<tr>
<td>Taking anticoagulants that should not be stopped</td>
<td>Less than 30</td>
</tr>
<tr>
<td>Pre-procedures/surgery with anticipated major blood loss, epidural anesthesia, lumbar puncture, significant bleeding</td>
<td>Less than 50</td>
</tr>
<tr>
<td>Pre-neurosurgery, head trauma (exception: patient with intra-cranial hemorrhage, not requiring surgery, taking anti-platelet agents – increased morbidity)</td>
<td>Less than 100</td>
</tr>
<tr>
<td>If bleeding and platelet dysfunction (i.e., medications: aspirin, clopidogrel; post cardiopulmonary bypass)</td>
<td>Any platelet count</td>
</tr>
</tbody>
</table>

Note: Immune thrombocytopenia (ITP) with life threatening bleeding, clinical situation specific with hematology consultation
Transfusion Guidelines:  
Platelet Transfusion - Dose & Details

Adults:

• 1 dose (Pooled or Apheresis), minimum platelet count is 240 x10^9/dose (mean approximately 330 x10^9/dose)

• Volume: Pooled - mean 317 mL  
  Apheresis - mean 223 mL

• Platelets shelf-life: 7 days, stored at 20-24°C  
  on an approved, monitored agitator

• Transfuse over 60 minutes, slower if TACO risk

• If pre-procedure, transfuse just prior to procedure

• Re-check platelet count 10 to 60 minutes after platelet is transfused

• 1 dose = 15-25 x10^9/L increase in platelet count at 10 to 60 minutes post transfusion

Learn More  Canadian Blood Services, Circular of Information [Scroll down, click on Pooled Platelets LR, CPD, Apheresis Platelets]
Transfusion Guidelines:
Plasma Transfusion - Indications

Rationale: Plasma contains all the coagulation factors necessary for the clotting process to stop bleeding.

Adults, consider if:

• Active bleeding or prior to major procedure*/surgery, and patient** with INR ≥ 1.8 due to multiple coagulation factor deficiency (if no coagulation factor concentrates or alternatives available).

  * Radiology procedures (major) with bleeding risk include: lumbar puncture or spinal procedure with hematoma risk, arterial intervention, biliary tract intervention or TIPS procedure, deep abscess drainage, urinary tract intervention, solid organ biopsy.

  ** Liver disease patients: the liver synthesizes all coagulation factors (procoagulant and anticoagulant); hemostatic pathways are rebalanced; often correction of abnormal INR is not needed before a procedure.

Note: Plasma should not be used for urgent reversal of warfarin unless prothrombin complex concentrate (PCC) is unavailable or contraindicated (history of heparin-induced thrombocytopenia).
Transfusion Guidelines:
Plasma Transfusion - Dose & Details

Adults

• 10 to 15 mL/kg; Ordered in units: Small adult - 3 units, Large adult - 4 units
• Volume:
  o 1 unit = about 250 mL [Frozen plasma (FP), Apheresis fresh frozen plasma (AFFP)]
  o some “double” or 2 units = about 500 mL (AFFP)
• Plasma shelf-life: up to 1 year, stored frozen at ≤ minus 18°C in approved, monitored freezer
• Thawing plasma requires about 30 minutes of time
• Transfuse each unit over 30 minutes to 2 hours, slower if TACO risk
• 1 dose increases coagulation factors about 20 % for about 6 hours
• As indicated, check INR, PTT 10 to 60 minutes post-transfusion

Note: Thawed 250 mL plasma can be stored refrigerated in TML for up to 5 days (120 hours)
Thawed 500 mL plasma can be stored refrigerated in TML for up to 24 hours
Objectives/Outline

After completing this learning participants will be able to:

- Describe the transfusionist’s actions to ensure safe transfusion administration.

Outline:

<table>
<thead>
<tr>
<th>Pre-Transfusion</th>
<th>Refer to slide number:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Topic:</td>
<td></td>
</tr>
<tr>
<td>Transfusion Order</td>
<td>10</td>
</tr>
<tr>
<td>Informed Consent</td>
<td>11</td>
</tr>
<tr>
<td>Group &amp; Screen</td>
<td>13-20</td>
</tr>
<tr>
<td>The Test: ABO &amp; Rh(D) Group and Antibody Screen</td>
<td>13-17</td>
</tr>
<tr>
<td>Using Test Results/Compatibility</td>
<td>18-19</td>
</tr>
<tr>
<td>Sample Collection</td>
<td>20</td>
</tr>
<tr>
<td>Preparing the Patient</td>
<td>21</td>
</tr>
<tr>
<td>TACO (Transfusion Associated Circulatory Overload)</td>
<td>22</td>
</tr>
<tr>
<td>IV Access/Fluids/Medications/Infusion Devices</td>
<td>23</td>
</tr>
<tr>
<td>Tubing/Filter</td>
<td>24</td>
</tr>
<tr>
<td>Picking Up Blood</td>
<td>25</td>
</tr>
</tbody>
</table>
Pre-transfusion:

Transfusion Order

Transfusionist must ensure:

• Indication for transfusion (patient signs & symptoms, laboratory test results) and dose align with transfusion guidelines

• Knowledge of component/product specific administration details


Order must include:

• Patient’s surname, first name and unique identification number & Date to be given

• Blood component/blood product & Number of units/doses

• Rate or duration of infusion, e.g. 150 mL/hour or over 2 hours (or per hospital standard protocol)

• Medication orders, if any (premedication or diuretic)

• Special modifications or requirements, if any (washed/irradiated)

• Blood warmer/rapid infusion device, if needed (or per hospital protocol)

• Sequence for transfusion of multiple components/products
Pre-transfusion: Informed Consent

• Required for blood transfusion
• Obtained by health care professional **prescribing** the transfusion
• Valid for the current course of treatment or hospital admission

Note: In emergency situations with life or health threatening bleeding, prescriber may declare that transfusion proceed without informed consent

Transfusionist role:
• Confirm hospital policy/procedure has been fulfilled prior to transfusion
• If informed consent has not been completed for a non-emergency transfusion, do not transfuse, advise the prescriber
• Advocate for patient; Facilitate the informed consent process

Information to engage in patient dialogue
For complete transfusion risk details, **BEBA Handbook**, pages 118-119
Pre-transfusion:
Group & Screen – ABO Blood Groups

A current group & screen test is essential for transfusion of compatible blood components (incompatible [antigen/antibody] transfusion can lead to life-threatening, acute hemolysis).

**Group: ABO blood groups**

Test patient sample: presence or absence of A and B antigens on the red blood cells
presence or absence of anti-A and anti-B antibodies in the plasma

In the ABO system, antibodies are naturally acquired, starting at 4 months of age.

- If the antigen is present on the surface of the red blood cells, then the corresponding antibody will **NOT** be in the plasma.
- If the antigen is **NOT** present on the surface of the red blood cells, then the corresponding antibody will be in the plasma.
Pre-transfusion: Group & Screen – Rh(D) Blood Groups

A current group & screen test is essential for transfusion of compatible blood components (incompatible [antigen/antibody] transfusion can lead to life-threatening, acute hemolysis).

**Group: Rh(D) blood group**

Test patient sample: presence or absence of D antigen on the red blood cells

- **GROUP Rh(D) POSITIVE**
- **GROUP Rh(D) NEGATIVE**

**Rh(D) Blood Group: Anti-D Antibody**

- In the Rh(D) system, anti-D antibody is NOT naturally occurring and is NOT in the plasma of:
  - Rh(D) positive patients
  - Rh(D) negative patients UNLESS exposed to the D antigen and then anti-D may be produced
- Rh(D) negative individuals can be exposed to the D antigen (and then may produce anti-D) through:
  - Transfusion of Rh(D) positive RBC
  - Transfusion of Rh(D) positive platelets (platelets may contain small amounts of red blood cells)
  - Pregnancy/delivery of an Rh(D) positive fetus
Pre-transfusion:
Group & Screen – Antibody Screen (1)

A current group & screen test is essential for transfusion of compatible blood components (incompatible [antigen/antibody] transfusion can lead to life-threatening, acute hemolysis).

**Screen: Antibody Screen**

- In addition to antigens A & B, human red blood cells have many antigens.
- If exposed to foreign red blood cell antigens via pregnancy or transfusion, antibodies against these antigens may develop.
- Some antibodies are **clinically significant**; they can cause life-threatening acute hemolysis (break down or destruction) of red blood cells that have the corresponding antigen.

Antibodies formed against the antigens on this red blood cell are clinically significant.
Pre-transfusion:
Group & Screen – Antibody Screen (2)

A current group & screen test is essential for transfusion of compatible blood components (incompatible [antigen/antibody] transfusion can lead to life-threatening, acute hemolysis).

**Screen: Antibody Screen**

- TML tests the serum (plasma part of blood sample) to rule out or to identify any of the clinically significant antibodies
- If all clinically significant antibodies are ruled out, the antibody screen is reported as negative
- If clinically significant antibody(ies) are identified, then compatible RBC units for transfusion to that patient must be negative for the corresponding antigen(s) (e.g., anti-c and anti-Jk^a^ identified in patient’s blood sample, then RBC units for transfusion must be antigens c- and Jka-)

**TML uses the patient’s Group & Screen test results to select compatible blood components for transfusion to that patient.**

---

[Learn More](#) Group & Screen [BEBA Handbook](#), pages 20-25
Pre-transfusion:
Group & Screen – Group: Summary

A current group & screen test is essential for transfusion of compatible blood components (incompatible [antigen/antibody] transfusion can lead to life-threatening, acute hemolysis).

| ABO Blood Groups (if antigen present, then antibody absent; if antigen absent, then antibody present) ABO antibodies are naturally acquired starting at 4 months of age |
|-----------------|-----------------|------------------|
| Blood Group     | ABO Antigen(s) on red blood cells | ABO Antibody(ies) in plasma |
| O               | none             | anti-A, anti-B    |
| A               | A                | anti-B            |
| B               | B                | anti-A            |
| AB              | A, B             | none              |

| Rh(D) Blood Groups (antigen present or absent; no naturally occurring anti-D antibody) |
|-----------------|-----------------|------------------|
| Blood Group     | Rh(D) Antigen on red blood cells | Rh(D) Antibody in plasma |
| Rh(D) Positive  | D                | none              |
| Rh(D) Negative  | none             | none; if exposed to Rh(D) antigen (pregnancy or transfusion), then anti-D may be produced |
Pre-transfusion: Group & Screen – Using Test Results/Compatibility (1)

TML uses the patient’s Group & Screen test results to select compatible blood components for transfusion to that patient, guided by ABO & Rh(D) compatibility table.

<table>
<thead>
<tr>
<th>Patient ABO/Rh(D) Blood Group</th>
<th>Compatible Blood Group for Transfusion</th>
<th>RBC</th>
<th>Platelets</th>
<th>Plasma</th>
<th>Cryoprecipitate</th>
</tr>
</thead>
<tbody>
<tr>
<td>O Positive</td>
<td>O</td>
<td>O preferred** Rh(D) positive or negative</td>
<td>O, A, B, AB</td>
<td></td>
<td></td>
</tr>
<tr>
<td>O Negative</td>
<td>O</td>
<td>O preferred** Rh(D) negative*</td>
<td>O, A, B, AB</td>
<td></td>
<td></td>
</tr>
<tr>
<td>A Positive</td>
<td>A, O</td>
<td>A preferred** Rh(D) positive or negative</td>
<td>A, AB</td>
<td></td>
<td></td>
</tr>
<tr>
<td>A Negative</td>
<td>A, O</td>
<td>A preferred** Rh(D) negative*</td>
<td>A, AB</td>
<td></td>
<td></td>
</tr>
<tr>
<td>B Positive</td>
<td>B, O</td>
<td>B preferred** Rh(D) positive or negative</td>
<td>B, AB</td>
<td></td>
<td></td>
</tr>
<tr>
<td>B Negative</td>
<td>B, O</td>
<td>B preferred** Rh(D) negative*</td>
<td>B, AB</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AB Positive</td>
<td>AB, A, B, O</td>
<td>AB preferred** Rh(D) positive or negative</td>
<td>AB</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AB Negative</td>
<td>AB, A, B, O</td>
<td>AB preferred** Rh(D) negative*</td>
<td>AB</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* In urgent bleeding patient situations or during times of short supply, Rh(D) negative patients may need to receive Rh(D) positive RBC and platelets.

** Platelets should be ABO compatible with patient’s red blood cells (donor platelets are suspended in plasma). In urgent bleeding patient situations or during times of short supply, TML will follow established policies for ABO group substitution for platelets.

Note: Very infrequently used component. Cryoprecipitate is interchangeable with Fibrinogen Concentrate for fibrinogen replacement.
Pre-transfusion:
Group & Screen – Using Test Results/Compatibility (2)

RBC Transfusion:
- Must be crossmatched (after group & screen test, TML procedure to detect any incompatibility between donor RBC unit & patient)
- Donor RBC unit must be ABO & Rh(D) identical or compatible to patient
- If patient’s antibody screen identified clinically significant antibody(ies), then donor RBC unit must be corresponding antigen negative

Platelet Transfusion:
- Donor platelet dose ideally is ABO & Rh(D) identical to patient
- Should be ABO plasma compatible (i.e., compatible with the patient’s red blood cells as donor platelets are suspended in plasma)
- If in short supply (occurs often), TML follows policy re: ABO group substitution; ABO plasma incompatible platelets may be transfused

Platelet Transfusion:
- Donor plasma unit ABO identical or compatible to patient
- Rh(D) blood group is not relevant for plasma transfusion (plasma has no red blood cells [i.e., no antigens])

Blood Products (Plasma Protein Products)
- ABO and Rh(D) blood group compatibility is not relevant (blood products are manufactured in lots, from plasma combined from many donors of diverse ABO blood groups).
**Pre-transfusion:**

**Group & Screen – Sample Collection**

---

Meticulous attention to sample collection procedure is essential for patient safety!

### Step 1:
- In the presence of the patient, confirm **patient’s surname, first name and unique identification number** on the patient’s armband and the sample label are identical.
- Some hospitals use bar-code scanning (positive patient identification) systems.

### Step 2:
- Immediately after collecting the blood sample, **place the label** on the **tube of blood at the patient’s bedside**.
- Labelling a sample away from the patient greatly increases risk of mislabelling.

### Step 3:
- **Document that you collected the sample.** You are documenting your accountability for unequivocal (unmistakable) patient identification.

### Note:
- If patient was transfused or pregnant within the preceding 3 months (or if unknown), the blood sample for crossmatching RBC units must be collected within 96 hours prior to transfusion (ensures patient has not formed any new antibodies related to recent transfusion or pregnancy).

### Note:
- To issue non-group O, ABO compatible RBC, TML requires two separate blood group determinations
  - One determination must be from current blood sample
  - Second determination:
    - from historical record if previous test completed,
    - or a separate sample collection,
    - or if sample collection using bar-code scanning, re-test current sample.
Pre-transfusion:

Preparing the Patient

Patient must be wearing a patient identification armband.

- Educate the patient about what to expect during transfusion (i.e., periodic assessments, vital sign checks, symptoms indicative of a transfusion reaction).

- Assess if history of previous transfusions.
  If so, assess if special requirements, or antibody card, or transfusion reactions.
  If indicated, follow up with prescriber and/or TML.

- Evaluate each transfusion for each patient for Transfusion Associated Circulatory Overload (TACO) risk factors.
  If indicated, follow up with prescriber for prevention strategies.
Pre-transfusion: Transfusion Associated Circulatory Overload (TACO)

- Leading cause of transfusion related deaths; PREVENTION is imperative
- Occurs secondary to transfusion at a rapid rate and/or the specific patient’s cardiac capacity is unable to tolerate transfusion volume.
- Signs: acute/worsening respiratory distress, decreased oxygen saturation, tachycardia, increased blood pressure, acute pulmonary edema

**TACO Risk Factors**
- Advanced age
- History of heart failure
- History of myocardial infarction
- Left ventricular dysfunction
- Renal dysfunction
- Positive fluid balance

**TACO Prevention Strategies**
- Transfuse only 1 unit at a time
- Transfuse slowly over longer time period (maximum 4 hours)
- **Pre-transfusion diuretic**
  (PO – 30 minutes prior; IV – just prior)
- TML to divide unit (if equipment available, then transfuse each part over maximum 4 hours)

If risk, review with prescriber for prevention strategies
Pre-transfusion: IV Access/Fluids/Medications/Infusion Devices

IV Access
- Confirm IV patent; Dedicated site - peripheral or central venous (if multiple lumen central line, a specific lumen for only the blood)
- Adult transfusion IV gauge: Routine - 20 to 22; Rapid - 14 to 18

IV Fluids
- Blood is compatible with only 0.9% sodium chloride (Exception – IVIG, some brands are compatible with only 5% Dextrose in water; refer to brand specific product monograph).

IV Medications
- Do not infuse any medication concurrently with blood (all medications are incompatible).
- If a medication must be given during transfusion, flush IV site with 0.9% sodium chloride flush syringes pre and post medication administration.

Infusion Devices
- Use only if device is Health Canada Medical Device Regulations approved.
- To transfuse blood (RBC, platelets, plasma, IVIG etc.), an infusion pump may be used.
- If ordered, blood warmers and rapid infusers can be used for RBC and plasma transfusion.

Note: Hemolysis can occur with RBC transfusion if: IV gauge too small, IV solutions other than 0.9 % sodium chloride used, improper storage leading to inadvertent heating or freezing, and infusion device malfunctions.
Pre-transfusion:

Tubing/Filter

• RBC, platelets and plasma must be transfused via blood tubing with 170 - 260 micron filter (captures any fibrin debris).

• Platelet transfusion:
  Always use NEW/FRESH blood tubing/filter (If filter was previously used, the platelets will adhere to fibrin captured in the filter; platelets are sticky!).

• Prime with blood or 0.9% sodium chloride

• Change after a maximum of 4 units of blood or 4 hours of time

• Be prepared for a potential transfusion reaction.
  Set up IV tubing such that if the transfusion must be stopped abruptly, then IV access can be maintained:
  o 0.9% sodium chloride flush syringes and an IV line with any IV solution are on hand, ready to infuse TKVO

  OR

  o 0.9% sodium chloride IV line is on hand, ready to infuse TKVO
Pre-transfusion:  
Picking Up Blood

For patient safety, ensure all pre-transfusion preparation steps have been completed before picking up blood from TML

- RBC, platelets, and plasma transfusion must be completed within 4 hours of issue from TML (i.e., removal from temperature controlled environment).
- NEVER store blood in medication or patient care area refrigerators (temperature is not regulated)
- TML requires documentation of patient identification (surname, first name and unique identification number) to issue blood to patient care area.
- Many hospitals have a form (e.g., pick up slip) which includes the required information
Objectives/Outline

After completing this learning participants will be able to:

- Describe the transfusionist’s actions to ensure safe transfusion administration.

Outline:

<table>
<thead>
<tr>
<th>Administering Transfusion</th>
<th>Refer to slide number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Topic:</td>
<td></td>
</tr>
<tr>
<td>Emergency Transfusion</td>
<td>27</td>
</tr>
<tr>
<td>Checking Blood</td>
<td>28-34</td>
</tr>
<tr>
<td>Patient Identification</td>
<td>29</td>
</tr>
<tr>
<td>ABO, Rh(D) Blood Groups</td>
<td>30-32</td>
</tr>
<tr>
<td>Unit number/Lot number</td>
<td>33</td>
</tr>
<tr>
<td>Expiry &amp; Visual Inspection</td>
<td>34</td>
</tr>
<tr>
<td>Assessments &amp; Vital Signs</td>
<td>35</td>
</tr>
<tr>
<td>Rate of Infusion</td>
<td>36</td>
</tr>
<tr>
<td>Completing Transfusion</td>
<td>37</td>
</tr>
<tr>
<td>Documentation</td>
<td>38</td>
</tr>
</tbody>
</table>
### Administering Transfusion: Emergency Transfusion: Uncrossmatched Blood

#### Emergency Transfusion - Life/health threatening bleeding

<table>
<thead>
<tr>
<th>Uncrossmatched Blood - ABO, Rh(D) Blood Group</th>
</tr>
</thead>
</table>

| RBC Transfusion                               |
| Group O Rh(D) negative for females age 45 years and under with childbearing potential |
| Group O Rh(D) positive for all others          |
| Note: Females age 45 years and under with childbearing potential, if possible should receive antigen K (K1 or Kell) negative RBC unless known to be K positive |

| Platelet Transfusion                          |
| Based on available supply, TML will follow established policies for ABO and Rh(D) blood group |

| Plasma Transfusion                            |
| Group AB (Rh(D) blood group is not relevant for plasma transfusion) |

| Fibrinogen Replacement                        |
| Fibrinogen Concentrate & Cryoprecipitate (infrequently used) are interchangeable |

- If uncrossmatched blood is transfused, prescriber must document that clinical situation justifies transfusion.
- Compatibility testing (group and screen, crossmatch) should be completed ASAP, and blood components of the appropriate group issued.
- Platelets: never refrigerate or place in a transport cooler

Administering Transfusion: Checking Blood

• Unequivocal (unmistakeable) identification of the patient is mandatory.
• Patient must be wearing a patient identification armband.
• Patient identification information must remain attached to blood during transfusion.

• For safety, at the bedside in the presence of the patient, follow 4 steps
  1. Patient Identification
  2. ABO, Rh(D) Blood Groups
  3. Unit number/Lot number
  4. Expiry & Visual Inspection

Checking Blood BEBA Handbook, pages 34-39
Administering Transfusion:
Checking Blood 1. Patient Identification

- Check **surname, first name, unique identification number** are identical on armband, transfusion order, transfusion label & chart label/issue form

---

**COTTAGE HOSPITAL DEEP WOODS REGION**

**PATIENT CARE ORDERS**

Date fields on this report are in format DD/MM/YY

**PATIENT:** Locks, Goldie  
**ACCT #:** MZ0000001/21  
**DOB:** 24/07/66  
**AGE/EX:** 22/F  
**HIN:**  
**REG DR:** Bear, Robert A  
**UK #:** M0000001/21  
**REG DIS:**

**BED:** 3  
**STATUS:** REG RCR

**LOCATION:** GO-HOME  
**ROOM:** B-000  
**PT PHONE:**

**PRODUCT:** RBC (RED CELL CONCENTRATE)  
**AMOUNT:** 1 unit  
**DATE OF TRANSFUSION:** today ASAP  
**INFUSION RATE:** over 2 hours  
**MEDICATION:** none  
**COMMENTS:**

**PRESCRIBER:** Dr. Robert Bear pagen 1-9876  
**DATE:** 26/05/21

---

**DEEP WOODS REGIONAL LABORATORY MEDICINE PROGRAM**

**UNIT ISSUE TRANSFUSION FORM**

**DATE:** 26/05/21

**DATE FORMATS ON THIS REPORT ARE IN THE FORMAT DD/MM/YY**

**PATIENT:** Locks, Goldie  
**MRN #:** M0000001/21  
**A POSITIVE**  
**TYPEX #:** 22/F  
**LOCATION:** GO-HOME  
**SPEC #:** 2605 BBB0003R

**PRODUCT:** RED CELL CONCENTRATE  
**PRODUCT UNIT #:** C06021317655  
**A POSITIVE**

**COMPATIBLE:** P 26/05/21 1418  
**ISSUED:** 26/05/21 1428  
**BIBBY:**  
**ISSUE COMMENTS:**

**DATE OF TRANSFUSION:**

**TIME TRANSFUSION BEGAN**

**AMOUNT:** 350 ML  
**SIGNATURES:**

**UNIT ADMINISTERED BY:**  
**CHECKED BY:**  
**TRANSFUSION COMMENTS:**

---

www.transfusionontario.org
Administering Transfusion:
Checking Blood 2. ABO, Rh(D) Blood Groups

- **Check ABO, Rh(D) Blood Groups** (only for blood components, not relevant for blood products) are identical/compatible on Group & screen test, CBS label, transfusion label & chart label/issue form.
Administering Transfusion: 
Checking Blood - ABO, Rh(D) Identical/Compatible

In this example the patient and blood component ABO and Rh(D) blood groups are identical. If the ABO and Rh(D) blood groups are not identical, then check the Compatibility Chart to confirm blood component ABO/Rh(D) blood groups are compatible with the patient's ABO and Rh(D) blood groups.

<table>
<thead>
<tr>
<th>Patient ABO/Rh(D) Blood Group</th>
<th>Compatible Blood Group for Transfusion</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>RBC</td>
</tr>
<tr>
<td>O Positive</td>
<td>O</td>
</tr>
<tr>
<td>Rh(D) positive or negative</td>
<td></td>
</tr>
<tr>
<td>O Negative</td>
<td>O</td>
</tr>
<tr>
<td>Rh(D) negative*</td>
<td></td>
</tr>
<tr>
<td>A Positive</td>
<td>A, O</td>
</tr>
<tr>
<td>Rh(D) positive or negative</td>
<td></td>
</tr>
<tr>
<td>A Negative</td>
<td>A, O</td>
</tr>
<tr>
<td>Rh(D) negative*</td>
<td></td>
</tr>
<tr>
<td>B Positive</td>
<td>B, O</td>
</tr>
<tr>
<td>Rh(D) positive or negative</td>
<td></td>
</tr>
<tr>
<td>B Negative</td>
<td>B, O</td>
</tr>
<tr>
<td>Rh(D) negative*</td>
<td></td>
</tr>
<tr>
<td>AB Positive</td>
<td>AB, A, B, O</td>
</tr>
<tr>
<td>Rh(D) positive or negative</td>
<td></td>
</tr>
<tr>
<td>AB Negative</td>
<td>AB, A, B, O</td>
</tr>
<tr>
<td>Rh(D) negative*</td>
<td></td>
</tr>
</tbody>
</table>

Note: Very infrequently used component. Cryoprecipitate is interchangeable with Fibrinogen Concentrate for fibrinogen replacement.

* In urgent bleeding patient situations or during times of short supply, Rh(D) negative patients may need to receive Rh(D) positive RBC and platelets.
** Platelets should be ABO compatible with patient's red blood cells (donor platelets are suspended in plasma).
In urgent bleeding patient situations or during times of short supply, TML will follow established policies for ABO group substitution for platelets.
Administering Transfusion:
Checking Blood - Patient Special Requirements

- TML provides blood as available per inventory and transfusion urgency. If transfusion will be delayed or if not available, then TML advises prescriber

**Antigen Negative RBC:**
- If group & screen identified clinically significant antibody, then confirm on CBS label the RBC unit is antigen negative e.g., patient has anti-Jka, RBC unit: antigen Jka-

**K Negative RBC:**
- If patient female, age 45 years and under with childbearing potential, then confirm on CBS label the RBC unit is antigen K- (unless patient is known K positive)
- Rationale: to prevent anti-K antibody in females who may become pregnant; Anti-K antibody in the mother could cross the placenta and hemolyse the red blood cells of an antigen K positive fetus leading to Hemolytic Disease of the Fetus and Newborn

**Irradiated RBC or Platelet:**
- If patient requires irradiated blood, then confirm CBS irradiated label is on blood bag

---

**Note**

In this example, the patient is female, age 22 years, and should receive antigen K- RBC transfusion. Review the lower right hand section of the CBS label; the unit is K-.
Administering Transfusion:
Checking Blood 3. Unit Number/Lot Number

- Check the **Unit number** (blood components)/Lot number (blood products) are **identical** on CBS label (blood components)/manufacturer label (blood products), transfusion label & chart label/issue form.
Administering Transfusion: Checking Blood 4. Expiry & Visual Inspection

Expiry

- Check **time of issue** (removal from temperature controlled environment) on chart label/issue form
- Blood expires 4 hours from time of issue, transfusion must be completed or any remainder discarded

**Note:** In this example, the issue time is 1420 hours 26/05/21. The RBC unit expires 4 hours later at 1820 hours 26/05/21. By 1820 hours the transfusion must be completed or any remainder discarded.

Visual Inspection

Check the **blood bag** for

- Any clots
- Unusual colour
- Ports are intact, no leaking

Click to review the [CBS Visual Assessment Guide](https://www.transfusionontario.org)
Administering Transfusion: Assessments & Vital Signs

• **Baseline assessment:** recent fevers, rashes, oxygen required, laboured respiration, chest auscultation if TACO risk

• **Vital signs parameters:** temperature, blood pressure, pulse, respiratory rate, oxygen saturation

• **Minimum frequency**
  (Hospital specific policy details regarding patient assessment & vital signs may be more extensive)
  - Baseline within 30 minutes prior to starting transfusion
  - 15 minutes after start of transfusion
  - After transfusion is completed
  - Periodically post-transfusion (reactions may occur up to 4 hours after transfusion; for dyspnea reactions, up to 24 hours after transfusion)
  - If a transfusion reaction is suspected
Administering Transfusion: Rate of Infusion

- If patient’s clinical status permits (i.e., patient stable, not bleeding; transfusion not urgent) initiate blood component transfusion cautiously and slowly.

- Adults: for the first 15 minutes, suggested rate is 50 mL/hour
- Assess patient and re-check vital signs after 15 minutes

- If no signs/symptoms of transfusion reaction, increase to rate ordered (slower if TACO risk; maximum is 4 hours from time of issue from TML).

- Usual rate per unit: RBC over 2 hours
  - Platelets over 60 minutes
  - Plasma over 30 minutes to 2 hours

**Note:** If blood tubing was primed with 0.9% sodium chloride, then re-prime tubing with blood component to ensure initial slow infusion rate is actually infusing blood component (blood tubing volume is 12-15 mL).
Administering Transfusion: Completing Transfusion

• Comply with expiry time specific to blood component/blood product being transfused

• **Expiry for Blood Components:** within 4 hours of time issued from TML (removal from the temperature controlled environment) Outside expiry time, discard any remainder

• Flush blood tubing with 0.9% sodium chloride

• Re-assess patient and vital signs

• Disconnect blood tubing when transfusion is completed (tubing can harbour bacteria)

• Hospital may require returning the empty blood bag to TML, otherwise dispose in biohazardous waste
Administering Transfusion: Documentation

- File completed chart label/issue form (includes documentation mandated per Transfusion Medicine standards) for each component or product transfused on patient’s health record.

- Transfusionist must complete chart label/issue form by adding:
  - Start and finish date/time (confirms transfusion completed within expiry time; provides time reference point, if transfusion reaction)
  - Their identity

- Document patient care: assessments, vital signs, volume on intake/output record
- If a transfusion reaction is suspected, document signs/symptoms, patient care
- Hospital policy may require completed “transfusion record” be returned to TML
Objectives/Outline

After completing this learning participants will be able to:
• Identify signs and symptoms and immediate management actions of a possible transfusion reaction.

Outline:

<table>
<thead>
<tr>
<th>Transfusion Reactions</th>
<th>Refer to slide number:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Topic:</td>
<td></td>
</tr>
<tr>
<td>Signs &amp; Symptoms</td>
<td>40</td>
</tr>
<tr>
<td>Immediate Actions</td>
<td>41</td>
</tr>
</tbody>
</table>
Transfusion Reactions: Signs & Symptoms

- Reactions can be categorized by key signs & symptoms:
  - Fever
  - Urticaria (hives)
  - Dyspnea
  - Hypotension

- Additional signs & symptoms include:
  Airway or Facial Edema, Anxiety, Coughing, Diffuse bleeding/oozing, Hemoglobinuria, Hypertension, Itching, Nausea/Vomiting, Pain (Back, Headache, IV site), Rash, Shaking Chills/Rigors, Subjective Chills, Tachycardia, Urine colour – dark/red, Wheezing

- Signs & symptoms may occur during transfusion or within 4 hours post-transfusion, for dyspnea reactions up to 24 hours post-transfusion

- The initial presenting sign/symptom may evolve, if so re-assess with prescriber and re-contact TML. Close patient monitoring is essential.
Transfusion Reactions:  Immediate Actions

• If a possible acute transfusion reaction is suspected:
  o Stop the transfusion
  o Maintain IV access
  o Check vital signs
  o Verify patient armband identification matches with transfusion label
  o Notify prescriber
  o Patient care as per order
  o Report reaction to TML
  o Document all details

• All unexpected, unusual or serious symptom(s) must be identified, managed and reported to TML for investigation. TML must report certain reactions to CBS/product manufacturer and Health Canada.
Bloody Easy Blood Administration: Summary – Transfusion Checklist

<table>
<thead>
<tr>
<th>PRE-TRANSFUSION</th>
<th>TRANSFUSION</th>
<th>POST-TRANSFUSION</th>
</tr>
</thead>
<tbody>
<tr>
<td>✓ Informed Consent</td>
<td>✓ Checking Blood Components/Blood Products</td>
<td>✓ Completing the Transfusion</td>
</tr>
<tr>
<td>• Per policy/procedure, questions addressed</td>
<td>• Blood received matches transfusion order</td>
<td>• Comply with expiry time specific for blood component/blood product</td>
</tr>
<tr>
<td>• Exception: emergent, life-threatening bleed</td>
<td>• At bedside, in physical presence of patient</td>
<td>Outside the expiry time, discard remainder</td>
</tr>
<tr>
<td>✓ Transfusion Order</td>
<td>✓ 1. Patient Identification: surname, first name, unique identification number identical on armband, order, transfusion &amp; chart label/tag</td>
<td>• Component tubing: flush with 0.9 % NaCl</td>
</tr>
<tr>
<td>• Indication supported: labs, signs, symptoms</td>
<td>• 2. ABO, Rh(D) Blood Groups (only for Components): identical/compatible on Group &amp; screen test, CBS (Canadian Blood Services) label, transfusion &amp; chart label/tag</td>
<td>Products given IV: flush (tubing/IV site) with compatible IV fluid</td>
</tr>
<tr>
<td>• Complete, required information included</td>
<td>• 3. Unit (Components) / Lot (Products)</td>
<td>• Some hospitals require returning the empty blood bag to TML</td>
</tr>
<tr>
<td>✓ Group &amp; Screen Testing</td>
<td>Number: identical on CBS label (Components) / manufacturer label (Products), transfusion &amp; chart label/tag</td>
<td>Otherwise dispose of blood tubing/bags in biohazardous waste</td>
</tr>
<tr>
<td>• Required for compatible blood components</td>
<td>• 4. Visual Inspection &amp; Expiry</td>
<td>• Re-assess patient and re-check vital signs:</td>
</tr>
<tr>
<td>• ABO, Rh(D) blood groups, antibody screen (clinically significant antibodies)</td>
<td>Components: no clots, usual colour, ports intact, expires 4 hours after issue from TML</td>
<td>- at end of transfusion</td>
</tr>
<tr>
<td>• Label tube of blood at patient’s bedside</td>
<td>Products: packaging/seed intact, colour as per manufacturer, vials/glass bottles – once entered/spiked, expires after 4 hours</td>
<td>- periodically post-transfusion (reactions may occur 4 hours post-transfusion; for dyspnea reactions up to 24 hours post transfusion)</td>
</tr>
<tr>
<td>✓ Prepare the Patient</td>
<td>✓ Patient Assessment and Vital Signs (for each unit)</td>
<td>✓ Documentation</td>
</tr>
<tr>
<td>• Educate: symptoms indicative of reaction</td>
<td>• Close monitoring/observation required</td>
<td>• File completed chart label/tag for each component or product transfused on patient’s health record (include start and stop times)</td>
</tr>
<tr>
<td>• Assess for transfusion history and TACO risk factors; follow up if indicated</td>
<td>• Minimum: within 30 minutes of starting, 15 minutes after starting, upon completion</td>
<td>Some hospitals require a completed “transfusion record” form returned to TML</td>
</tr>
<tr>
<td>✓ Prepare the Equipment</td>
<td>• Temp, BP, pulse, respiratory rate, oxygen saturation; if TACO risk - chest auscultation</td>
<td>• Record volume transfused, vital signs and patient assessments</td>
</tr>
<tr>
<td>• Dedicated, patient IV (peripheral or central)</td>
<td>• Infusion Rate (for each unit)</td>
<td>• If a transfusion reaction is suspected: report to TML, document signs and symptoms, patient care</td>
</tr>
<tr>
<td>• Compatible IV fluid (only 0.9 % NaCl (sodium chloride) for blood components)</td>
<td>• 50 mL/hour for first 15 minutes; can be deferred if acute bleeding</td>
<td></td>
</tr>
<tr>
<td>• Blood components – tubing/filter (170-260 microns); change after 4 units or required</td>
<td>• Re-check after 15 minutes, if no indication of reaction then increase to rate as ordered</td>
<td></td>
</tr>
<tr>
<td>• Platelets – always NEW/FRESH tubing/filter</td>
<td>✓ Possible Transfusion Reaction</td>
<td></td>
</tr>
<tr>
<td>• Prime tubing/filter: blood or compatible IV fluid</td>
<td>• If any adverse/unexpected/serious symptoms, STOP transfusion, refer to TISS Reaction Chart</td>
<td></td>
</tr>
<tr>
<td>• IV setup to stop abruptly &amp; maintain TKVO: 0.9% NaCl flush syringes + any fluid IV line or 0.9% NaCl IV line</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Infusion Devices: if Health Canada approved</td>
<td></td>
<td></td>
</tr>
<tr>
<td>✓ Pick Up Blood from TML (Transfusion Medicine Lab)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Patient identification (surname, first name, unique identification number) and order</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

June 2021, version 1.0 Ontario Regional Blood Coordinating Network

www.transfusionontario.org
**Glossary of Terms (1)**

**Agglutination:** the clumping and sticking together of normally free cells or bacteria or other small particles forming visible aggregates

**Apheresis:** blood collection method where an individual component is collected directly via a cell separator machine, can be used to collect platelets or plasma

**Blood Component:** a therapeutic part of blood intended for transfusion (e.g., RBC, platelets, granulocytes, plasma, cryoprecipitate)

**Blood Product:** a therapeutic product derived from human blood or plasma and produced by a manufacturing process, also referred to as plasma protein product (e.g., albumin, coagulation products, factor concentrates, immunoglobulins)

**Clinically Significant Antibodies:** are antibodies with potential to cause harm to transfused patients or to affect their management and treatment; include antibodies capable of causing acute and delayed hemolytic transfusion reactions (HTR) or hemolytic disease of the fetus and newborn (HDFN)

**Crossmatch:** when RBC transfusion is ordered and group and screen testing completed, the TML procedure to detect any incompatibilities between recipient and donor

- **Computer (electronic) crossmatch** — computerized procedure that is used in place of a serologic crossmatch to detect ABO incompatibility (applicable only if antibody screen is negative)
- **Serologic crossmatch** — in vitro test performed between donor red cells (from a segment removed from the RBC unit) and recipient’s serum or plasma (from the group and screen blood sample) to determine compatibility

**Direct Antiglobulin Test (DAT):** a blood test that determines if there is in vivo binding of immunoglobulin or complement on the red blood cells (in vivo sensitization). It is used for detection and differential diagnosis of several forms of immune hemolysis (such as hemolytic transfusion reactions). Interpreting the clinical significance of a DAT result includes considering the patient’s clinical history as well as other laboratory test results.

**Dispense:** release of blood components or blood products from TML (temperature controlled environment) to the clinical area, synonymous with issue.
Glossary of Terms (2)

**Health Care Professional**: a person associated with either a specialty or a discipline and who is qualified and allowed by regulatory bodies to provide a healthcare service to a patient.

**Hemolysis**: breakdown or lysis of red blood cells

**Issue**: release of blood components or blood products from TML (temperature controlled environment) to the clinical area, synonymous with dispense

**Plasma Protein Product**: a therapeutic product derived from human blood or plasma and produced by a manufacturing process, also referred to as blood product (e.g., albumin, coagulation factor concentrates, immunoglobulins)

**Positive Patient Identification Technology**: refers to a computerized system that scans a barcode, radiofrequency identification (RFID) or another electronically readable element on a patient’s identification band to confirm identity

**Prescriber**: for this learning, refers to health care professionals who are authorized to order transfusion of blood components and blood products (physicians, physician assistants, nurse practitioners, midwives, dentists)

**Red Blood Cells**: the cellular component of blood that transports oxygen from the lungs to the tissue cells. Oxygen is needed for tissue cells to carry out their functions in the body

**TIPS procedure**: Radiology procedure to insert a transjugular intrahepatic portosystemic shunt (TIPS) to decrease pressure in the portal vein in liver cirrhosis patients

**Transfusion Medicine Laboratory (TML)**: also known as the Blood Bank or Transfusion Service

**Transfusionist**: Regulated health care professional who administers a blood transfusion
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>AFFP</td>
<td>Apheresis fresh frozen plasma (blood component)</td>
</tr>
<tr>
<td>AKI</td>
<td>Acute kidney injury</td>
</tr>
<tr>
<td>ASAP</td>
<td>As soon as possible</td>
</tr>
<tr>
<td>CBS</td>
<td>Canadian Blood Services</td>
</tr>
<tr>
<td>DAT</td>
<td>Direct antiglobulin test</td>
</tr>
<tr>
<td>DIC</td>
<td>Disseminated intravascular coagulation</td>
</tr>
<tr>
<td>FC</td>
<td>Fibrinogen Concentrate</td>
</tr>
<tr>
<td>FP</td>
<td>Frozen plasma (blood component)</td>
</tr>
<tr>
<td>HLA</td>
<td>Human leukocyte antigen</td>
</tr>
<tr>
<td>HPA</td>
<td>Human platelet antigen</td>
</tr>
<tr>
<td>IVIG</td>
<td>Intravenous immunoglobulin</td>
</tr>
<tr>
<td>LR</td>
<td>Leukocytes reduced</td>
</tr>
<tr>
<td>MHP</td>
<td>Massive Hemorrhage Protocol</td>
</tr>
<tr>
<td>mL</td>
<td>milliliter</td>
</tr>
<tr>
<td>MOH</td>
<td>Ontario Ministry of Health</td>
</tr>
<tr>
<td>PCC</td>
<td>Prothrombin Complex Concentrate</td>
</tr>
<tr>
<td>PLT</td>
<td>platelet count, laboratory value</td>
</tr>
<tr>
<td>PPP</td>
<td>Plasma protein products, also known as blood products</td>
</tr>
<tr>
<td>RBC</td>
<td>Red blood cell concentrate unit (blood component)</td>
</tr>
<tr>
<td>Rh</td>
<td>Rhesus blood group</td>
</tr>
<tr>
<td>RhIG</td>
<td>Rh(D) Immune Globulin</td>
</tr>
<tr>
<td>SCIG</td>
<td>Subcutaneous immunoglobulin</td>
</tr>
<tr>
<td>TACO</td>
<td>Transfusion Associated Circulatory Overload</td>
</tr>
<tr>
<td>TA-GvHD</td>
<td>Transfusion Associated Graft Versus Host Disease</td>
</tr>
<tr>
<td>TKVO</td>
<td>To keep vein open</td>
</tr>
<tr>
<td>TML</td>
<td>Transfusion Medicine Laboratory</td>
</tr>
<tr>
<td>TRALI</td>
<td>Transfusion Related Acute Lung Injury</td>
</tr>
<tr>
<td>TTISS-ON</td>
<td>Ontario Transfusion Transmitted Injuries Surveillance System</td>
</tr>
</tbody>
</table>


Acknowledgements

• The Ontario Regional Blood Coordinating Network (ORBCoN) gratefully acknowledges funding support provided by the Ontario Ministry of Health. The views expressed in this presentation are those of the authors and of ORBCoN and do not necessarily reflect those of the Ontario Ministry of Health or the Government of Ontario.

• Many thanks to my ORBCoN and Transfusion Medicine family and friends for their ongoing mentorship and support.
General Disclaimer

The publisher, author(s)/general editor(s) and every person involved in the creation of this resource, whether directly or indirectly, shall not be liable for any loss, injury, claim, liability or damage of any kind resulting from the use of or reliance on any information or material contained in this resource. This resource is intended for information purposes only, without any warranties of any kind. Without limitation, the resource is not intended or designed to constitute or replace medical advice or to be used for diagnosis. If specific information on personal health matters is sought, advice from a physician or other appropriate health professional should be obtained. Any decision involving patient care should be based on the judgement of the attending physician according to the needs and condition of each individual patient. The publisher, author(s)/general editor(s) and every person involved in the creation of this resource disclaim all liability in respect of the results of any actions taken in reliance upon information contained in this resource and for any errors or omissions in the resource. They expressly disclaim liability to any user/reader of the resource.
Questions

Email: bertad@mcmaster.ca